Peripheral Microvascular Blood Flow in ANOCA

Sponsor
Amsterdam UMC, location VUmc (Other)
Overall Status
Recruiting
CT.gov ID
NCT05610410
Collaborator
Maastricht University Medical Center (Other)
109
1
35
3.1

Study Details

Study Description

Brief Summary

An observational cross-sectional cohort study investigating whether peripheral endothelial function assessed using Laser speckle contrast analysis and coronary endothelial function measured with invasive coronary function testing are correlated in patients with angina and no obstructive coronary arteries.

Condition or Disease Intervention/Treatment Phase
  • Other: Laser speckle contrast analysis

Detailed Description

Rationale: Coronary endothelial dysfunction (CED) has been proposed to cause signs and symptoms of myocardial ischaemia in patients with angina but no obstructive coronary artery disease (INOCA) and has been proposed to play an important role in the pathophysiology of heart failure with preserved ejection fraction, as an element of the pro-inflammatory state causing cardiac functional and structural abnormalities in this syndrome. Research has shown that patients with coronary microvascular dysfunction (CMD) often present with echocardiographic signs of diastolic dysfunction combined with higher rates of detectable cardiac troponin and are at increased risk of developing HFpEF, indicating a major overlap in the complex pathophysiology underlying these syndromes. CED is associated with an increased risk of adverse cardiac events and currently can only be detected with invasive coronary function testing (ICFT).

However, it has been suggested that CED is a component of systemic endothelial dysfunction and is associated with endothelial dysfunction in other microvascular beds. The cutaneous microcirculation is suitable for microvascular function studies and has been shown to correlate with muscle microvascular function. The recently developed Laser speckle contrast analysis (LASCA) technique enables non-invasive monitoring of microvascular blood flow in superficial microvascular beds. In combination with iontophoresis of acetylcholine, nitroprusside and insulin, LASCA allows evaluation of peripheral microvascular endothelial and smooth muscle function. While LASCA is an established technique, the association between CED diagnosed with ICFT and an abnormal peripheral endothelial function measured by LASCA is currently unknown.

Objective: The primary objective of the study is to test whether peripheral endothelial function assessed using Laser speckle contrast analysis and CED measured with ICFT are correlated.

Study design: Observational cross-sectional cohort study.

Study population: 51 patients over the age of 18 with signs and symptoms of ischemia with no obstructive coronary arteries (INOCA) and a clinical indication for ICFT because of persistent angina without obstructive coronary artery disease and 58 patients with HFpEF and a clinical indication for ICFT.

Primary study endpoint: The main study end point is the difference in peripheral endothelial function between patients with and without CED measured with ICFT in the INOCA group and the HFpEF group.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Study participants do not benefit from participation in this study. The burden of this study is low. The aim is that study procedures will be performed within 24 hours of the elective ICFT and study participants do not have to come to the hospital for an additional visit. The total risks associated with participation are classified as being low, because the risks for adverse events and serious adverse events from a local and transient stimulus in skin are minimal. Iontophoresis of acetylcholine, nitroprusside and insulin does not cause any skin damage and the used dosages are very small and as such, the stimuli do not cause any systemic effects.

Study Design

Study Type:
Observational
Anticipated Enrollment :
109 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Relationship Between Regulation of Peripheral and Intracoronary Microvascular Blood Flow in Patients With Ischemia and no Obstructive Coronary Arteries
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients with angina and no obstructive coronary arteries

Other: Laser speckle contrast analysis
Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
Other Names:
  • EndoPAT
  • Patients with HFpEF

    Other: Laser speckle contrast analysis
    Peripheral endothelial function assessment using Laser speckle contrast analysis and Peripheral reactive hyperemia assessment using EndoPAT
    Other Names:
  • EndoPAT
  • Outcome Measures

    Primary Outcome Measures

    1. Peripheral endothelial function [1-1,5 hour]

      Peripheral endothelial function measured with LASCA between ANOCA patients with and without Coronary endothelial dysfunction

    Secondary Outcome Measures

    1. Microvascular reactivity measurement methods [1-1,5 hour]

      The relationship between microvascular reactivity measured using EndoPAT and LASCA in patients with ANOCA or HFpEF.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Clinical indication for elective invasive coronary function test (ICFT)

    • Suited for one of the study groups:

    • Persistent angina, defined as symptoms of angina; or

    • HFpEF, diagnosed according to the ESC 2021 heart failure guidelines

    • Absence of obstructive CAD, documented before inclusion, defined as

    • CCTA - indicative of absence of obstructed coronary arteries, or

    • CAG - <50% diameter stenosis (DS) in the epicardial coronary arteries or (fractional flow reserve (FFR) >0.80 or instant wave free ratio (iFR) >0.89)

    Exclusion Criteria:
    • Under 18 years of age

    • Unable or unwilling to undergo ICFT

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Amsterdam UMC, lcoation VUmc Amsterdam Netherlands

    Sponsors and Collaborators

    • Amsterdam UMC, location VUmc
    • Maastricht University Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Y. Appelman, MD, PhD, FESC, Amsterdam UMC, location VUmc
    ClinicalTrials.gov Identifier:
    NCT05610410
    Other Study ID Numbers:
    • VUmc_2021.0615
    First Posted:
    Nov 9, 2022
    Last Update Posted:
    Nov 9, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 9, 2022